News

Phase 2 trial results suggest the possibility of a treatment that may regenerate brain cells following TBI.

Dozens of doctors and other medical professionals have been charged with exchanging opioids and other drugs for sex and cash; the first 2 patients in the United States have been treated with CRISPR; doctors have cured infants of immunodeficiency syndrome using gene therapy made from HIV.

A phase III trial evaluated intermediate-dose cytarabine plus granulocyte-colony stimulating factor (G-CSF) vs G-CSF alone prior to autoSCT in multiple myeloma.

Academic medical centers and a group representing community oncology practices have both raised concerns about CMS’ proposed reimbursement plan for chimeric antigen receptor (CAR) T-cell therapy, the individually manufactured gene treatments that are revolutionizing cancer care. The plan will be finalized next month, a year after the federal government launched a national coverage analysis to determine how to pay for these lifesaving yet expensive cancer treatments.

Patients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.

In this article, important concepts in the molecular testing of non–small-cell lung cancer are highlighted.

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

Prasad S. Adusumilli, MD, sheds light on the preliminary phase I data from a trial of CAR T-cell therapy in malignant pleural disease from mesothelioma.

Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.

The planned phase 1/2 trial of the recombinant AAV5 vector treatment, the first one-time administered AAV gene therapy to enter clinical testing for Huntington disease, is expected to begin dosing patients in the second half of 2019.

Researchers have identified a potential new target for CAR T-cell therapy in patients with multiple myeloma.

Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.

The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

Recent work looking at the response to immune checkpoint blockade (ICB) therapy given before surgery for advanced melanoma found increased infiltration of B cells, a type of white blood cell, in patients who responded to therapy compared with those who did not.

Sequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplant.

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Experts shared the challenges they've encountered in integrating novel treatments such as CAR T-cell therapy into practice at the 2019 NCCN Annual Conference.

A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Sergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for patients with relapsed myeloma.

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.

There is concern among stakeholder groups that references to “hospital” could mean that community practices would be unable to be reimbursed by Medicare under a proposed National Coverage Determination.

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.

In a rare clinical trial, stem cell transplantation appeared to provide greater protection against MS progression than DMT.

Noopur Raje, MD, discusses the current treatment landscape of multiple myeloma, with a specific focus on available triplet regimens and the recent data with chimeric antigen receptor T-cell therapy.